Theravance Biopharma (TBPH) Projected to Announce Earnings on Tuesday

Theravance Biopharma (NASDAQ:TBPH) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of $0.0725 per share and revenue of $22.4940 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 5:00 PM ET.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. On average, analysts expect Theravance Biopharma to post $2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Theravance Biopharma Stock Up 0.0%

Shares of NASDAQ:TBPH traded up $0.01 during trading on Tuesday, reaching $16.88. 111,987 shares of the company traded hands, compared to its average volume of 571,834. The firm has a fifty day simple moving average of $16.72 and a 200 day simple moving average of $17.00. Theravance Biopharma has a 1-year low of $10.99 and a 1-year high of $21.03. The firm has a market cap of $869.91 million, a P/E ratio of 7.67 and a beta of 0.19.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha sold 37,799 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the sale, the insider owned 9,174,453 shares of the company’s stock, valued at $155,965,701. This trade represents a 0.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the transaction, the senior vice president owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. Tower Research Capital LLC TRC increased its holdings in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares in the last quarter. Creative Planning increased its stake in shares of Theravance Biopharma by 6.7% in the third quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock valued at $196,000 after buying an additional 842 shares in the last quarter. State of Wyoming raised its holdings in shares of Theravance Biopharma by 5.7% in the second quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 1,019 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Theravance Biopharma by 6.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 1,020 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Theravance Biopharma by 12.1% in the fourth quarter. Royal Bank of Canada now owns 9,464 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 1,024 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TBPH has been the subject of several recent research reports. JonesTrading lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and boosted their price target for the company from $15.00 to $17.00 in a research note on Tuesday, July 7th. BTIG Research lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. B. Riley Financial raised their target price on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, April 7th. Finally, Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. Eight research analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $19.40.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.